| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
11,498 |
9,717 |
$2.48M |
| 99284 |
Emergency department visit for the evaluation and management, high severity |
6,437 |
5,026 |
$1.61M |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
5,459 |
4,777 |
$1.40M |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
2,854 |
2,202 |
$719K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
3,376 |
2,970 |
$643K |
| 70450 |
Computed tomography, head or brain; without contrast material |
834 |
691 |
$371K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
1,843 |
1,679 |
$250K |
| 97112 |
Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination |
4,277 |
1,700 |
$139K |
| 97530 |
Therapeutic activities, direct patient contact, each 15 minutes |
3,829 |
1,693 |
$110K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
591 |
532 |
$90K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
2,358 |
2,167 |
$86K |
| 99281 |
Emergency department visit for the evaluation and management, self-limited or minor |
393 |
345 |
$82K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
939 |
878 |
$72K |
| 74177 |
Computed tomography, abdomen and pelvis; with contrast material |
169 |
138 |
$64K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
715 |
643 |
$60K |
| 97140 |
Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) |
1,668 |
703 |
$53K |
| 80053 |
Comprehensive metabolic panel |
4,926 |
4,157 |
$41K |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
236 |
215 |
$39K |
| 80050 |
General health panel |
1,618 |
1,486 |
$35K |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
766 |
623 |
$31K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
6,353 |
5,241 |
$31K |
| 80061 |
Lipid panel |
2,280 |
2,078 |
$29K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
604 |
529 |
$28K |
| 96361 |
Intravenous infusion, hydration; each additional hour |
25 |
23 |
$27K |
| 71046 |
Radiologic examination, chest; 2 views |
1,057 |
937 |
$26K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
3,288 |
2,848 |
$25K |
| G0463 |
Hospital outpatient clinic visit for assessment and management of a patient |
642 |
526 |
$22K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
1,836 |
1,698 |
$19K |
| 92507 |
Treatment of speech, language, voice, communication, and/or auditory processing disorder |
380 |
66 |
$16K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
1,038 |
946 |
$16K |
| 74176 |
Computed tomography, abdomen and pelvis; without contrast material |
34 |
30 |
$15K |
| 84443 |
Thyroid stimulating hormone (TSH) |
1,205 |
1,097 |
$15K |
| 97110 |
Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion |
626 |
269 |
$14K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
1,220 |
896 |
$12K |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
473 |
420 |
$12K |
| 84484 |
|
1,947 |
1,309 |
$10K |
| 85610 |
|
1,232 |
868 |
$10K |
| 71045 |
Radiologic examination, chest; single view |
1,755 |
1,404 |
$9K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
26 |
25 |
$8K |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
1,249 |
1,125 |
$8K |
| 80051 |
|
1,122 |
942 |
$7K |
| 93010 |
Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only |
1,473 |
1,256 |
$7K |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
515 |
455 |
$7K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
733 |
648 |
$7K |
| 82565 |
|
1,538 |
1,307 |
$7K |
| 96365 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour |
13 |
13 |
$6K |
| 83690 |
|
1,318 |
1,157 |
$6K |
| 83735 |
|
1,318 |
1,054 |
$6K |
| 97162 |
|
137 |
118 |
$6K |
| 81001 |
|
1,687 |
1,529 |
$5K |
| G0483 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed |
32 |
28 |
$4K |
| 87801 |
Infectious agent detection by nucleic acid; amplified probe, multiple organisms |
114 |
101 |
$4K |
| 94761 |
|
2,020 |
1,744 |
$4K |
| 87081 |
|
434 |
411 |
$4K |
| 82607 |
|
244 |
226 |
$3K |
| 81025 |
|
413 |
374 |
$3K |
| 83880 |
|
261 |
224 |
$3K |
| 36415 |
Collection of venous blood by venipuncture |
3,686 |
3,035 |
$3K |
| 87077 |
|
375 |
299 |
$3K |
| 82077 |
|
262 |
213 |
$2K |
| 80306 |
|
169 |
156 |
$2K |
| 82947 |
|
758 |
677 |
$2K |
| 87186 |
|
313 |
260 |
$2K |
| 84460 |
|
466 |
409 |
$2K |
| 81003 |
|
895 |
820 |
$2K |
| 85027 |
|
389 |
342 |
$2K |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
1,479 |
1,016 |
$2K |
| 82043 |
|
157 |
146 |
$1K |
| 84520 |
|
512 |
453 |
$1K |
| 83605 |
|
311 |
247 |
$1K |
| 80305 |
|
90 |
82 |
$1K |
| 73630 |
|
28 |
24 |
$1K |
| 82728 |
|
84 |
77 |
$1K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
67 |
57 |
$939.98 |
| 73030 |
|
16 |
15 |
$752.78 |
| 90688 |
|
23 |
22 |
$632.75 |
| 87040 |
|
129 |
63 |
$546.04 |
| 84439 |
|
56 |
53 |
$481.04 |
| 82746 |
|
31 |
28 |
$462.50 |
| Q3014 |
Telehealth originating site facility fee |
23 |
12 |
$389.44 |
| 87420 |
|
21 |
19 |
$386.77 |
| 83540 |
|
61 |
56 |
$372.61 |
| 86140 |
|
85 |
70 |
$361.87 |
| 0241U |
Neonatal screening for hereditary disorders, genomic sequence analysis panel |
13 |
12 |
$359.10 |
| 82962 |
|
148 |
92 |
$352.24 |
| 85007 |
|
133 |
122 |
$251.46 |
| 82150 |
|
47 |
42 |
$240.02 |
| 84466 |
|
14 |
13 |
$212.16 |
| 85379 |
|
40 |
40 |
$210.40 |
| 83550 |
|
29 |
26 |
$202.68 |
| 84481 |
|
13 |
13 |
$166.20 |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
55 |
51 |
$141.79 |
| 84075 |
|
32 |
26 |
$131.70 |
| 85730 |
|
24 |
24 |
$108.18 |
| 73610 |
|
14 |
13 |
$102.61 |
| 82550 |
|
15 |
14 |
$85.56 |
| 85652 |
|
34 |
27 |
$85.26 |
| 82553 |
|
14 |
13 |
$71.15 |
| 96375 |
Therapeutic injection; each additional sequential IV push |
16 |
16 |
$70.90 |
| J7030 |
Infusion, normal saline solution , 1000 cc |
1,840 |
1,499 |
$39.21 |
| 82247 |
|
16 |
14 |
$38.16 |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
826 |
723 |
$33.29 |
| 74019 |
|
13 |
12 |
$33.19 |
| 36592 |
|
184 |
177 |
$33.11 |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
831 |
720 |
$30.88 |
| J7050 |
Infusion, normal saline solution, 250 cc |
1,622 |
908 |
$19.52 |
| J1170 |
Injection, hydromorphone, up to 4 mg |
95 |
81 |
$14.31 |
| A9270 |
Non-covered item or service |
2,836 |
767 |
$8.61 |
| J2270 |
Injection, morphine sulfate, up to 10 mg |
222 |
197 |
$0.54 |
| Q0162 |
Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen |
58 |
53 |
$0.00 |
| J3490 |
Unclassified drugs |
31 |
24 |
$0.00 |
| J1200 |
Injection, diphenhydramine hcl, up to 50 mg |
16 |
12 |
$0.00 |